Transfemoral-Transcaval Liver Biopsy (TFTC) and Transjugular Liver Biopsy (TJLB) in Patients with Fontan-Associated Liver Disease (FALD).

Biopsy FALD Fontan Liver biopsy Transfemoral Liver Biopsy Transjugular Liver Biopsy

Journal

Cardiovascular and interventional radiology
ISSN: 1432-086X
Titre abrégé: Cardiovasc Intervent Radiol
Pays: United States
ID NLM: 8003538

Informations de publication

Date de publication:
30 May 2024
Historique:
received: 13 09 2023
accepted: 15 05 2024
medline: 31 5 2024
pubmed: 31 5 2024
entrez: 30 5 2024
Statut: aheadofprint

Résumé

To describe our experience in performing transfemoral-transcaval liver biopsy (TFTC) and transjugular liver biopsy (TJLB) in patients with Fontan-associated liver disease (FALD). A single-center, retrospective review of 23 TFTC and seven TJLB performed between August 2011 and May 2023 on patients who previously underwent the Fontan procedure (median age 23.1 years, ranging 11-43 years, 48% female). Patient demographics, laboratory values, pathology, radiology, and cardiology reports were reviewed. Liver explants were correlated with histopathological evaluation to determine sampling accuracy when available. All biopsies achieved technical success (accurate targeting and safe tissue sample extraction) and histopathological success (yielding sufficient tissue for accurate diagnosis). Liver biopsies were performed during simultaneous cardiac catheterization in 28 of 30 (93%) procedures. There was no statistically significant change in hemoglobin, hematocrit, platelet count post-procedure, and fluoroscopy times. There was one major complication within the TJLB group and one minor complication within the TFTC group. Transvenous liver biopsies, whether via transfemoral or transjugular route, may be safely performed in FALD patients while yielding samples with technical and histopathological success. The transfemoral approach, which is our preferred method; its compatibility with simultaneous cardiac catheterization and its potentially increased safety profile stemming from the avoidance of transversing the Fontan shunt-makes it a particular advantageous option in the management of FALD.

Identifiants

pubmed: 38816503
doi: 10.1007/s00270-024-03761-6
pii: 10.1007/s00270-024-03761-6
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. The Author(s).

Références

Fontan F, Baudet E. Surgical repair of tricuspid atresia. Thorax. 1971;26(3):240–8.
doi: 10.1136/thx.26.3.240 pubmed: 5089489 pmcid: 1019078
Pundi KN, Johnson JN, Dearani JA, et al. 40-year follow-up after the Fontan operation: long-term outcomes of 1,052 patients. J Am Coll Cardiol. 2015;66(15):1700–10.
doi: 10.1016/j.jacc.2015.07.065 pubmed: 26449141
Daniels CJ, Bradley EA, Landzberg MJ, et al. Fontan-associated liver disease: proceedings from the American College Of Cardiology Stakeholders Meeting, October 1 to 2, 2015, Washington DC. J Am Coll Cardiol. 2017;70(25):3173–94.
doi: 10.1016/j.jacc.2017.10.045 pubmed: 29268929
Eipel C, Abshagen K, Vollmar B. Regulation of hepatic blood flow: the hepatic arterial buffer response revisited. World J Gastroenterol. 2010;16(48):6046–57.
doi: 10.3748/wjg.v16.i48.6046 pubmed: 21182219 pmcid: 3012579
Kiesewetter CH, Sheron N, Vettukattill JJ, et al. Hepatic changes in the failing Fontan circulation. Heart. 2007;93(5):579–84.
doi: 10.1136/hrt.2006.094516 pubmed: 17005713
Patel IJ, Rahim S, Davidson JC, et al. Society of interventional radiology consensus guidelines for the periprocedural management of thrombotic and bleeding risk in patients undergoing percutaneous image-guided interventions-part II: recommendations: endorsed by the Canadian Association for Interventional Radiology and the Cardiovascular and Interventional Radiological Society of Europe. J Vasc Interv Radiol JVIR. 2019;30(8):1168-1184.e1. https://doi.org/10.1016/j.jvir.2019.04.017 .
doi: 10.1016/j.jvir.2019.04.017 pubmed: 31229333
Khalilzadeh O, Baerlocher MO, Shyn PB, et al. Proposal of a new adverse event classification by the society of interventional radiology standards of practice committee. J Vasc Interv Radiol. 2017;28(10):1432-1437.e1433.
doi: 10.1016/j.jvir.2017.06.019 pubmed: 28757285
Cynamon J, Shabrang C, Golowa Y, Daftari A, Herman O, Jagust M. Transfemoral transcaval core-needle liver biopsy: an alternative to transjugular liver biopsy. J Vasc Interv Radiol. 2016;27(3):370–5.
doi: 10.1016/j.jvir.2015.11.030 pubmed: 26723528
Goldberg DJ, Surrey LF, Glatz AC, et al. Hepatic fibrosis is universal following Fontan operation, and severity is associated with time from surgery: a liver biopsy and hemodynamic study. J Am Heart Assoc. 2017;6(5):e004809.
doi: 10.1161/JAHA.116.004809 pubmed: 28446492 pmcid: 5524062
Munsterman ID, Duijnhouwer AL, Kendall TJ, et al. The clinical spectrum of Fontan-associated liver disease: results from a prospective multimodality screening cohort. Eur Heart J. 2019;40(13):1057–68.
doi: 10.1093/eurheartj/ehy620 pubmed: 30346512
Wu FM, Jonas MM, Opotowsky AR, et al. Portal and centrilobular hepatic fibrosis in Fontan circulation and clinical outcomes. J Heart Lung Transplant. 2015;34(7):883–91.
doi: 10.1016/j.healun.2015.01.993 pubmed: 25863891
Wang Y, Ganger DR, Levitsky J, et al. Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. Am J Roentgenol. 2011;196(3):553–61.
doi: 10.2214/AJR.10.4580
Louie CY, Pham MX, Daugherty TJ, Kambham N, Higgins JP. The liver in heart failure: a biopsy and explant series of the histopathologic and laboratory findings with a particular focus on pre-cardiac transplant evaluation. Mod Pathol. 2015;28(7):932–43.
doi: 10.1038/modpathol.2015.40 pubmed: 25793895
Dhall D, Kim SA, Mc Phaul C, et al. Heterogeneity of fibrosis in liver biopsies of patients with heart failure undergoing heart transplant evaluation. Am J Surg Pathol. 2018;42(12):1617–24.
doi: 10.1097/PAS.0000000000001163 pubmed: 30273196
Srinivasan A, Guzman AK, Rand EB, et al. Percutaneous liver biopsy in Fontan patients. Pediatr Radiol. 2019;49(3):342–50.
doi: 10.1007/s00247-018-4311-9 pubmed: 30506328
Guzman AK, Dodds K, Rychik J, et al. Percutaneous liver biopsy post-fontan operation: a single pediatric institutional experience. J Vasc Interv Radiol. 2014;25(3):S198.
doi: 10.1016/j.jvir.2013.12.534
Evans WN, Winn BJ, Yumiaco NS, et al. Transvenous hepatic biopsy in stable Fontan patients undergoing cardiac catheterization. Pediatr Cardiol. 2014;35(7):1273–8.
doi: 10.1007/s00246-014-0928-0 pubmed: 24817681
Rychik J, Atz AM, Celermajer DS, et al. Evaluation and management of the child and adult with Fontan circulation: a scientific statement from the American Heart Association. Circulation. 2019;140(6):e234–84.
doi: 10.1161/CIR.0000000000000696 pubmed: 31256636
Peng R, Wattamwar K, Kuc N, Jagust M, Golowa Y, Cynamon J. Transjugular versus transfemoral transcaval liver biopsy: a single-center experience in 500 cases. J Vasc Interv Radiol. 2020;31(9):1394–400.
doi: 10.1016/j.jvir.2020.05.024 pubmed: 32798119
Borquez AA, Silva-Sepulveda J, Lee JW, Vavinskaya V, Vodkin I, El-Sabrout H, Towbin R, Perry JC, Moore JW, El-Said HG. Transjugular liver biopsy for Fontan associated liver disease surveillance: technique, outcomes and hemodynamic correlation. Int J Cardiol. 2021;328:83–8. https://doi.org/10.1016/j.ijcard.2020.11.037 .
doi: 10.1016/j.ijcard.2020.11.037 pubmed: 33278420
Gelatt M, Hamilton RM, McCrindle BW, et al. Risk factors for atrial tachyarrhythmias after the Fontan operation. J Am Coll Cardiol. 1994;24(7):1735–41.
doi: 10.1016/0735-1097(94)90181-3 pubmed: 7963122
Dohan A, Guerrache Y, Dautry R, et al. Major complications due to transjugular liver biopsy: incidence, management and outcome. Diagn Interv Imaging. 2015;96(6):571–7.
doi: 10.1016/j.diii.2015.02.006 pubmed: 25771477
Kalambokis G, Manousou P, Vibhakorn S, et al. Transjugular liver biopsy–indications, adequacy, quality of specimens, and complications–a systematic review. J Hepatol. 2007;47(2):284–94.
doi: 10.1016/j.jhep.2007.05.001 pubmed: 17561303
McAfee JH, Keeffe EB, Lee RG, Rösch J. Transjugular liver biopsy. Hepatology. 1992;15(4):726–32.
doi: 10.1002/hep.1840150429 pubmed: 1551649

Auteurs

Muhammad Usman Shahid (MU)

Department of Interventional Radiology, University of Miami Miller School of Medicine, 1150 NW 14th Street, Miami, FL, 33136 , USA. Mus11@Med.Miami.Edu.

Yosef Frenkel (Y)

Division of Vascular and Interventional Radiology, Department of Radiology, Montefiore Medical Center, 111 E 210th St, Bronx, NY, 10467, USA.

Norbert Kuc (N)

Division of Vascular and Interventional Radiology, Department of Radiology, Montefiore Medical Center, 111 E 210th St, Bronx, NY, 10467, USA.

Yosef Golowa (Y)

Division of Vascular and Interventional Radiology, Department of Radiology, Montefiore Medical Center, 111 E 210th St, Bronx, NY, 10467, USA.

Jacob Cynamon (J)

Division of Vascular and Interventional Radiology, Department of Radiology, Montefiore Medical Center, 111 E 210th St, Bronx, NY, 10467, USA.

Classifications MeSH